Are you Dr. Verma?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3850 S. National Ave
Suite 600
Springfield, MO 65807Phone+1 417-882-4880Fax+1 417-882-7843
Summary
- Dr. Dushyant Verma, MD is an oncologist in Springfield, Missouri. He is currently licensed to practice medicine in Missouri, Louisiana, and Texas. He is affiliated with Cox Medical Centers.
Education & Training
- Louisiana State University School of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
- New York-Presbyterian Brooklyn Methodist HospitalResidency, Internal Medicine, 1998 - 2001
- Pt. B.D. Sharma Postgrad Institute of Medical ScienceClass of 1987
Certifications & Licensure
- TX State Medical License 2006 - 2026
- MO State Medical License 2001 - 2025
- LA State Medical License 2009 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2013
Publications & Presentations
PubMed
- 57 citationsSignificance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitorsLorenzo Falchi, Hagop M. Kantarjian, Xuemei Wang, Dushyant Verma, Alfonso Quintás-Cardama
American Journal of Hematology. 2013-12-01 - 86 citationsPrognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemiaFabio P.S. Santos, Dan Jones, Wei Qiao, Jorge E. Cortes, Farhad Ravandi
Cancer. 2011-05-15 - 10 citationsLong-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.Fabio P.S. Santos, Yesid Alvarado, Hagop M. Kantarjian, Dushyant Verma, Susan O'Brien
Cancer. 2011-03-01